🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Box Hill
Clinical trial register · Australia

Clinical Trials in Box Hill, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3331 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:46 UTC
3331
Studies in scope
all four open statuses
1807
Recruiting now
open to new participants
758
Lead sponsors
across recruiting studies
Top sites
Melbourne 25 Adelaide 22 Brisbane 22 Box Hill 16 Perth 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company16 AstraZeneca12 Janssen Research & Development, LLC10 Hoffmann-La Roche7 Merck Sharp & Dohme LLC5 Clear sponsor filter
Site location
Melbourne25 Adelaide22 Brisbane22 Box Hill16 Perth11
All 94 locations
Target enrolment
to

Trials with a site in Box Hill

16 of 3331 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Adelaide, Bedford Park, Box Hill, Brisbane, Heidelberg West, Maroochydore, Southport, Spearwood
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Botany, Box Hill, Brisbane, Camberwell, Geelong, Heidelberg West, Merewether, Oaklands Park
2026-02-10
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Adelaide, Box Hill, Brisbane, Melbourne, Parkville, Perth, Randwick, Westmead
2026-01-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Box Hill, Brisbane, Campbelltown, Heidelberg, Macquarie University, Perth, Randwick, St Albans
2025-12-12
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Adelaide, Blacktown, Box Hill, Brisbane, Bruce, Camberwell, Frankston, Garran
2025-12-01
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Box Hill, Brisbane, Canberra, Geelong, Meadowbrook, Perth, Southport, St Leonards
2025-10-31
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Adelaide, Box Hill, Brisbane, Broadmeadow, Geelong, Heidelberg, Ipswich, Murdoch
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Adelaide, Box Hill, Brisbane, Burwood, Clayton, Frankston, Geelong, Greenfields
2025-09-02
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
DrugRemternetug
Eli Lilly and Company
Phase 3
1,400
Birtinya, Botany, Box Hill, Camberwell, East Maitland, Herston, Ipswich, Ivanhoe
2024-10-24
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Adelaide, Botany, Box Hill, Brisbane, Brookvale, Camberwell, Garran, Geelong
2024-04-30
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Adelaide, Blacktown, Botany, Box Hill, Brisbane, Bruce, Camberwell, Clayton
2024-03-05
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Adelaide, Blacktown, Box Hill, Brisbane, Bruce, Camberwell, Clayton, Geelong
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Botany, Box Hill, Brisbane, Carlton, Erina, Ivanhoe, Kogarah, Malvern
2022-10-10
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Ballarat Central, Box Hill, Clayton, Coffs Harbour, Darlinghurst, Geelong, Hobart, Launceston
2022-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Darlinghurst, Woolloongabba, Kurralta Park, Box Hill, Melbourne
2021-10-04
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Adelaide, Box Hill, Brisbane, Maroochydore, Melbourne, Parkville
2018-07-18
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-australia/city/box-hill

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,331 studies in total at the last sync on 26 Sep 2026, 19:46 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Box Hill that also match the filters currently applied.

How many clinical trials are recruiting in Box Hill?

8 of the 16 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:46 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Box Hill), 16 studies
PhaseStudiesRecruitingShare
Phase 3168100%

Most active sponsors

Lead sponsors with the most studies (Box Hill)
Lead sponsorStudiesRecruiting
Eli Lilly and Company168
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.